Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Dana-Farber Cancer Institute

Sites in Boston, MA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1326
Shown on this page
12
Current sort
Recently updated
Campus scope
Dana-Farber Cancer Institute, Boston, MA
Additional filters apply within this campus.

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

Filter and sort this campus

These controls apply only within Dana-Farber Cancer Institute, Boston, MA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 973–984 of 1,326 matching trials with a site at Dana-Farber Cancer Institute, Boston, MA.
Indexed local directory records.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Stored official records

Recruiting Early Phase 1 Interventional

Vitamin D in Patients With Stage I-III Colon Cancer or Resectable Colon Cancer Liver Metastases

NCT02172651
Status at this site: Recruiting
View directory record Official record
Conditions
Stage I-III Colon Cancer, Stage IV Colon Cancer With Resectable Liver Metastases, Stage, Colon Cancer
Interventions
Placebo, Vitamin D3
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 13, 2026, 9:35 PM EDT
Active, not recruiting Phase 1 Interventional

Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC

NCT04846478
Site status not listed — check the official record
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
Interventions
Talazoparib, Tazemetostat
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 16, 2026, 3:16 AM EDT
Active, not recruiting Phase 2 Interventional

Venetoclax + Azacitidine vs. Induction Chemotherapy in AML

NCT04801797
Site status not listed — check the official record
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Cytarabine, Daunorubicin, Idarubicin, Liposomal daunorubicin and cytarabine, Venetoclax
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
9
States / cities
Duarte, California • Palo Alto, California • Sacramento, California + 4 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 15, 2026, 7:05 AM EDT
Active, not recruiting Not applicable Interventional Results available

Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS

NCT02926911
Site status not listed — check the official record
View directory record Official record
Conditions
DCIS, Ductal Carcinoma in Situ
Interventions
Active Monitoring, Surgery
Other
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
40 Years to 99 Years · Female only
Enrollment
997 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
141
States / cities
Anchorage, Alaska • Phoenix, Arizona • Duarte, California + 117 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 14, 2026, 1:42 AM EDT
Active, not recruiting No phase listed Observational

Male Breast Cancer: Understanding the Biology for Improved Patient Care

NCT01101425
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
17
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 21, 2026, 2:15 PM EDT
Recruiting Phase 2 Interventional

Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis

NCT04380740
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Graft Vs Host Disease
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
15
States / cities
Duarte, California • Tampa, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 15, 2026, 2:03 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Ibrutinib + Venetoclax in Untreated WM

NCT04273139
Site status not listed — check the official record
View directory record Official record
Conditions
MYD88 Gene Mutation, Waldenstrom Macroglobulinemia
Interventions
IBRUTINIB, Venetoclax
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 20, 2026, 9:58 AM EDT
Recruiting No phase listed Observational

Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas

NCT00843375
Status at this site: Recruiting
View directory record Official record
Conditions
Colonic Neoplasms
Interventions
Not listed
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
11
States / cities
Los Angeles, California • Urbana, Illinois • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Nov 4, 2026, 5:15 PM EST
Active, not recruiting Phase 2 Interventional Results available

Amivantamab in Adenoid Cystic Carcinoma

NCT05074940
Site status not listed — check the official record
View directory record Official record
Conditions
Salivary Gland Cancer
Interventions
Amivantamab
Drug
Lead sponsor
Trisha Wise-Draper
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
5
States / cities
La Jolla, California • Boston, Massachusetts • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 15, 2026, 11:48 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer

NCT03637543
Site status not listed — check the official record
View directory record Official record
Conditions
Prostate Cancer
Interventions
Nivolumab
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
5
States / cities
Boston, Massachusetts • South Weymouth, Massachusetts • Londonderry, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 15, 2026, 2:59 AM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

NCT06799026
Status at this site: Recruiting
View directory record Official record
Conditions
Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma
Interventions
DC/MM Fusion Vaccine, Elranatamab, GM-CSF
Biological · Drug
Lead sponsor
David Avigan
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 16, 2026, 11:09 AM EDT
Recruiting No phase listed Observational

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

NCT02269592
Status at this site: Recruiting
View directory record Official record
Conditions
B-cell Malignancy, Low-grade, Hematological Malignancies, IgG Monoclonal Gammopathy of Uncertain Significance, Monoclonal Gammopathy of Undetermined Significance (MGUS), Myelodysplastic Syndrome With Low-grade Lesions, Myelodysplastic Syndromes, Smoldering Multiple Myeloma, Waldenstrom Macroglobulinemia
Interventions
Not listed
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
7
States / cities
Boston, Massachusetts • Brighton, Massachusetts • Methuen, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 17, 2026, 2:15 AM EDT

About this Dana-Farber Cancer Institute institution page

What this page lists
ClinicalTrials.gov records that list Dana-Farber Cancer Institute in Boston, MA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Dana-Farber Cancer Institute at any site, browse by condition, or browse by U.S. city.